07:00 , Jul 10, 2008 |  BC Innovations  |  Targets & Mechanisms

New Resolve in Inflammation

A report in Nature Immunology describes how the endogenous molecule resolvin E1 promotes resolution of airway inflammation in mice and provides a rationale for using this molecule as a therapeutic agent to treat asthma. Company...
08:00 , Jan 14, 2008 |  BC Week In Review  |  Clinical News

OX-2477: Phase I start

This year, Orexo will begin a Phase I trial of oral OX-2477 in healthy volunteers. Orexo AB (SSE:ORX), Uppsala, Sweden   Product: OX-2477   Business: Inflammation   Molecular target: Eoxin   Description: Eoxin inhibitor  ...
08:00 , Nov 19, 2007 |  BC Week In Review  |  Company News

Biolipox, Orexo deal

NLA cetirizine is in Phase II testing to treat allergic and non-allergic rhinitis. BLX-CLI is a preclinical program for asthma and chronic obstructive pulmonary disease (COPD), and BLX-Eoxin consists of a portfolio of eoxin inhibitors...
07:00 , Oct 22, 2007 |  BC Week In Review  |  Company News

Biolipox, Orexo deal

ORX will acquire Biolipox for 8.6 million shares valued at SEK776.8 million ($120.9 million) based on ORX's close of SEK90.75 on Oct. 12, the last trading day before the deal was announced. Biolipox shareholders would...
07:00 , Oct 22, 2007 |  BioCentury  |  Strategy

One deal at a time

Orexo AB is acquiring Biolipox AB to add critical mass and put the company in a better position for future M&A. Orexo hopes a future purchase of a sales and marketing company will enable it...
01:55 , Oct 16, 2007 |  BC Extra  |  Company News

Orexo acquiring Biolipox

Orexo (SSE:ORX) proposed to acquire Biolipox (Stockholm, Sweden) for 8.6 million shares of ORX stock, which would value the inflammation, neurology and pulmonary company at SEK776.8 million ($120.9 million) based on ORX's close of SEK90.75...
08:00 , Jan 24, 2005 |  BioCentury  |  Tools & Techniques

Biolipox: Bypassing COX-2

With COX-2 inhibitors under fire, companies developing next-generation treatments in pain and inflammation are getting renewed attention from investors. One of the early stage plays, Biolipox AB , recently closed a $41 million C round...
07:00 , Jun 10, 2002 |  BioCentury  |  Emerging Company Profile

Biolipox: Arachidonic acid rocks

Among the many biotech companies spun out of Sweden's Karolinska Institutet in the past few years years, Biolipox AB has operated in stealth mode. Its scientific platform, based on the discovery of a novel metabolic...